| XLS |
|
|
|
€ million |
Q1 – 2014 |
Q1 – 2013 |
Profit after tax |
327.4 |
269.0 |
Items of other comprehensive income that will not be reclassified to profit or loss in subsequent periods: |
|
|
Remeasurement of the net defined benefit liability |
|
|
Changes in remeasurement |
–164.7 |
–87.8 |
Deferred taxes |
30.2 |
14.7 |
Changes recognized in equity |
–134.5 |
–73.1 |
|
–134.5 |
–73.1 |
Items of other comprehensive income that may be reclassified to profit or loss in subsequent periods: |
|
|
Available-for-sale financial assets |
|
|
Fair value adjustments |
–0.6 |
0.7 |
Reclassification to profit or loss |
1.7 |
– |
Deferred taxes |
–0.2 |
–0.4 |
Changes recognized in equity |
0.9 |
0.3 |
Derivative financial instruments |
|
|
Fair value adjustments |
–23.0 |
–21.4 |
Reclassification to profit or loss |
–14.0 |
–3.1 |
Reclassification to assets |
– |
– |
Deferred taxes |
8.8 |
7.5 |
Changes recognized in equity |
–28.2 |
–17.0 |
Exchange differences on translating foreign operations |
|
|
Changes taken directly to equity |
10.6 |
21.0 |
Reclassification to profit or loss |
– |
– |
Changes recognized in equity |
10.6 |
21.0 |
|
–16.7 |
4.3 |
Other comprehensive income |
–151.2 |
–68.8 |
Comprehensive income |
176.2 |
200.2 |
of which attributable to Merck KGaA shareholders |
171.1 |
195.4 |
of which attributable to non-controlling interests |
5.1 |
4.8 |
back
